Press Releases

NEWS RELEASE 09.12.2022

AMGEN ANNOUNCES WEBCAST OF 2022 BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE

NEWS RELEASE 09.12.2022

LUMAKRAS® (SOTORASIB) COMBINED WITH VECTIBIX® (PANITUMUMAB) SHOWS CONFIRMED 30% OBJECTIVE RESPONSE RATE IN PATIENTS WITH KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER

NEWS RELEASE 09.11.2022

LUMAKRAS®/LUMYKRAS® (SOTORASIB) DEMONSTRATES SUPERIOR PROGRESSION-FREE SURVIVAL OVER DOCETAXEL IN FIRST POSITIVE PHASE 3 TRIAL OF A KRAS G12C INHIBITOR IN NON-SMALL CELL LUNG CANCER

NEWS RELEASE 09.08.2022

AMGEN ANNOUNCES WEBCAST OF 2022 MORGAN STANLEY GLOBAL HEALTHCARE CONFERENCE

NEWS RELEASE 09.08.2022

AMGEN ANNOUNCES POSITIVE NEW DATA AT EADV 2022 FOR OTEZLA® (APREMILAST)

NEWS RELEASE 09.07.2022

AMGEN TO WEBCAST INVESTOR CALL AT ESMO 2022

NEWS RELEASE 09.02.2022

AMGEN ANNOUNCES WEBCAST OF 2022 WELLS FARGO HEALTHCARE CONFERENCE

NEWS RELEASE 09.02.2022

AMGEN ANNOUNCES WEBCAST OF 2022 CITI GLOBAL HEALTHCARE CONFERENCE

NEWS RELEASE 08.30.2022

AMGEN ANNOUNCES TOPLINE DATA FROM LUMAKRAS® (SOTORASIB) PHASE 3 TRIAL IN NON-SMALL CELL LUNG CANCER

NEWS RELEASE 08.30.2022

AMGEN TO PRESENT NEW, POSITIVE CLINICAL AND REAL-WORLD DATA ACROSS INFLAMMATION PORTFOLIO AT EADV 2022

NEWS RELEASE 08.29.2022

NEW AMGEN DATA AT ESC 2022 SHOW LONG-TERM LDL-C LOWERING WITH REPATHA® (EVOLOCUMAB) WAS WELL-TOLERATED FOR MORE THAN 8 YEARS

NEWS RELEASE 08.23.2022

AMGEN ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY OF ABP 959, BIOSIMILAR CANDIDATE TO SOLIRIS® (ECULIZUMAB)

NEWS RELEASE 08.22.2022

AMGEN TO PRESENT NEW DATA AT ESC CONGRESS 2022 HIGHLIGHTING UP TO 8.5 YEARS OF REPATHA® (EVOLOCUMAB) SAFETY AND TOLERABILITY DATA IN HIGH-RISK ASCVD PATIENT POPULATIONS

NEWS RELEASE 08.08.2022

AMGEN PRESENTS NEW TARLATAMAB CLINICAL DATA AT WCLC 2022

NEWS RELEASE 08.07.2022

AMGEN DATA AT WCLC 2022 HIGHLIGHTS POTENTIAL TO DELIVER TRANSFORMATIVE MEDICINES FOR HISTORICALLY DIFFICULT-TO-TREAT LUNG CANCERS

NEWS RELEASE 08.04.2022

AMGEN REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS

NEWS RELEASE 08.04.2022

AMGEN TO ACQUIRE CHEMOCENTRYX FOR $4 BILLION IN CASH

NEWS RELEASE 08.03.2022

AMGEN APPOINTS MICHAEL V. DRAKE TO BOARD OF DIRECTORS

NEWS RELEASE 08.03.2022

AMGEN ANNOUNCES 2022 THIRD QUARTER DIVIDEND

NEWS RELEASE 08.02.2022

AMGEN TO WEBCAST INVESTOR MEETING AT WCLC 2022

NEWS RELEASE 08.01.2022

AMGEN ANNOUNCES WEBCAST OF 2022 SECOND QUARTER FINANCIAL RESULTS

NEWS RELEASE 06.20.2022

AMGEN FOUNDATION MORE THAN DOUBLES COMMITMENT TO LABXCHANGE, FREE VIRTUAL SCIENCE EDUCATION PLATFORM

NEWS RELEASE 06.10.2022

AMGEN ANNOUNCES WEBCAST OF GOLDMAN SACHS 43RD ANNUAL HEALTHCARE CONFERENCE

NEWS RELEASE 06.06.2022

FDA APPROVES RIABNI™ (RITUXIMAB-ARRX), A BIOSIMILAR TO RITUXAN® (RITUXIMAB), FOR ADULTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS

NEWS RELEASE 06.05.2022

NEW HEAD-TO-HEAD DATA SHOW VECTIBIX® (PANITUMUMAB) DEMONSTRATED SUPERIOR OVERALL SURVIVAL COMPARED TO BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN JAPANESE PATIENTS WITH WILD-TYPE RAS COLORECTAL CANCER

NEWS RELEASE 06.03.2022

AMGEN ANNOUNCES WEBCAST OF 2022 JEFFERIES HEALTHCARE CONFERENCE

NEWS RELEASE 05.31.2022

AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 2 DATA FOR INVESTIGATIONAL OLPASIRAN IN ADULTS WITH ELEVATED LIPOPROTEIN(a)

NEWS RELEASE 05.26.2022

NEW DATA SHOWCASES HOW AMGEN IS ADVANCING ALL ANGLES OF CANCER CARE THROUGH INNOVATIVE ONCOLOGY PORTFOLIO AND PIPELINE AT ASCO 2022

NEWS RELEASE 05.12.2022

AMGEN AND LANCE BASS PARTNER TO ENCOURAGE PEOPLE TO DO A 'DOUBLE TAKE' TO RECOGNIZE THE EARLY SIGNS OF PSORIATIC ARTHRITIS

NEWS RELEASE 05.06.2022

AMGEN ANNOUNCES WEBCAST OF 2022 BANK OF AMERICA HEALTHCARE CONFERENCE

NEWS RELEASE 05.02.2022

AMGEN RELEASES ANNUAL ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT

NEWS RELEASE 04.27.2022

AMGEN REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS

NEWS RELEASE 04.27.2022

AMGEN ANNOUNCES RESULTS FROM TWO OPEN LABEL EXTENSION STUDIES OF REPATHA® (EVOLOCUMAB)

NEWS RELEASE 04.22.2022

AMGEN ANNOUNCES WEBCAST OF 2022 FIRST QUARTER FINANCIAL RESULTS

NEWS RELEASE 04.18.2022

AMGEN ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY OF ABP 654, BIOSIMILAR CANDIDATE TO STELARA® (USTEKINUMAB)

NEWS RELEASE 04.10.2022

LUMAKRAS® (SOTORASIB) CODEBREAK 100 STUDY SHOWS TWO-YEAR OVERALL SURVIVAL OF 32.5% IN PATIENTS WITH KRAS G12C-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER

NEWS RELEASE 03.25.2022

AMGEN ANNOUNCES NEW OTEZLA (APREMILAST) DATA AT AAD CONGRESS 2022

NEWS RELEASE 03.10.2022

Amgen To Present At The 32nd annual Oppenheimer Healthcare Conference

NEWS RELEASE 03.08.2022

AMGEN TO PRESENT LONG-TERM OUTCOMES FOR LUMAKRAS® (SOTORASIB) IN KRAS G12C-MUTATED NSCLC AT AACR 2022

NEWS RELEASE 03.07.2022

GLOBAL BIOTECHNOLOGY LEADER AMGEN BREAKS GROUND ON NEW MANUFACTURING FACILITY IN NORTH CAROLINA

NEWS RELEASE 03.02.2022

AMGEN TO PRESENT AT THE 42ND ANNUAL COWEN HEALTHCARE CONFERENCE

NEWS RELEASE 03.02.2022

AMGEN ANNOUNCES 2022 SECOND QUARTER DIVIDEND

NEWS RELEASE 02.26.2022

NEW DATA FURTHER REINFORCE EFFICACY OF TEZSPIRE™ (TEZEPELUMAB-EKKO) IN A BROAD POPULATION OF SEVERE ASTHMA PATIENTS

NEWS RELEASE 02.22.2022

AMGEN ISSUES INAUGURAL GREEN BOND TO ADVANCE ESG GOALS

NEWS RELEASE 02.16.2022

AMGEN RECOGNIZED FOR OUTSTANDING ESG PERFORMANCE

NEWS RELEASE 02.14.2022

LUMAKRAS® (SOTORASIB) SHOWS ENCOURAGING AND CLINICALLY MEANINGFUL ANTICANCER ACTIVITY IN PATIENTS WITH KRAS G12C-MUTATED ADVANCED PANCREATIC CANCER IN CODEBREAK 100 TRIAL

NEWS RELEASE 02.08.2022

AMGEN OUTLINES GROWTH STRATEGY THROUGH 2030 AT VIRTUAL BUSINESS REVIEW

NEWS RELEASE 02.08.2022

AMGEN PROVIDES LONG-TERM GUIDANCE THROUGH 2030 DURING BUSINESS REVIEW MEETING

NEWS RELEASE 02.07.2022

AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS

NEWS RELEASE 02.03.2022

AMGEN TO HOST VIRTUAL BUSINESS REVIEW MEETING

NEWS RELEASE 02.03.2022

AMGEN AND PLEXIUM ANNOUNCE MULTI-YEAR, DRUG DISCOVERY COLLABORATION TO IDENTIFY NOVEL TARGETED PROTEIN DEGRADATION THERAPIES

NEWS RELEASE 01.20.2022

LUMAKRAS® (SOTORASIB) RECEIVES APPROVAL IN JAPAN FOR PATIENTS WITH KRAS G12C-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER

NEWS RELEASE 01.13.2022

TEZSPIRE™ (TEZEPELUMAB-EKKO) NOW AVAILABLE IN THE UNITED STATES FOR THE TREATMENT OF SEVERE ASTHMA

NEWS RELEASE 01.11.2022

AMGEN AND ARRAKIS THERAPEUTICS ANNOUNCE MULTI-TARGET COLLABORATION TO IDENTIFY NOVEL RNA DEGRADER SMALL MOLECULE THERAPEUTICS

NEWS RELEASE 01.10.2022

AMGEN AND BIOLABS LA AT THE LUNDQUIST INSTITUTE ANNOUNCE THAT KARMA BIOTECHNOLOGIES WILL RECEIVE THE SECOND AMGEN GOLDEN TICKET

NEWS RELEASE 01.10.2022

EUROPEAN COMMISSION APPROVES LUMYKRAS® (SOTORASIB) FOR PATIENTS WITH KRAS G12C-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER

NEWS RELEASE 01.06.2022

AMGEN TO PRESENT AT THE 40TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

NEWS RELEASE 01.06.2022

Amgen and Generate Biomedicines Announce Multi-Target, Multi-Modality Research Collaboration Agreement

Earnings